Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Human Parvovirus 4: A harmless bystander or a pathogen of severe acute respiratory illness

Shantanu Prakash1, Suruchi Shukla1, Vangala Ramakrishna, Hricha Mishra, Amit K. Bhagat, Amita Jain*

Department of Microbiology, King Georges Medical University, Lucknow, UP, 226003, India

A R T I C L E   I N F O
Article history:
Received 16 July 2019
Received in revised form 30 September 2019
Accepted 1 October 2019
Corresponding Editor: Eskild Petersen, Aarhus, Denmark

Keywords:
PARV4 virus
Genotype
Severe acute respiratory illness
India

A B S T R A C T

Introduction: Severe Acute Respiratory Infection (SARI) is an important cause of morbidity and mortality worldwide, caused by a large number of viral and bacterial agents. PARV4 is a recently identified virus detected in human blood and variety of tissues, but its disease association with SARI could not be established.

Objective: In the present case control study, we aim to investigate the association of PARV4 with SARI.

Methods: The Nasal and Throat swab (NS/TS) samples of 241 cases and 146 healthy controls were tested for most common respiratory viruses and PARV4 by real-time PCR.

Results: PARV4 was detected in 64(26.55%) SARI cases and only one healthy control (0.68%). PARV4 was the most common viral agent detected in SARI cases. A strong association of PARV4 is seen with severe respiratory illness.

Conclusion: Detection of PARV4 in a significantly higher number of SARI cases, in comparison with controls, suggests association of PARV4 with SARI. PARV4 genotype 2 is the only circulating strain detected in our study.

© 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Severe Acute Respiratory Infection (SARI) is an important cause of morbidity and mortality worldwide, particularly in developing countries and among children under five years of age (GBD LRI Collaborators, 2017; GBD 2015 LRI Collaborators, 2017; World Health Organization, 2011). SARI is associated with viral and bacterial agents. Common viral agents are influenza A (InflA) and B (InflB) viruses, parainfluenza viruses (PIV), coronaviruses, respiratory syncytial viruses (RSV), adenoviruses (AV), and rhinoviruses. Influenza virus infection, in particular, is very common followed by respiratory syncytial virus (RSV) infection (CDC, 2016; Laguna-Torres et al., 2011; Chakunashvili et al., 2018; Kenmoe et al., 2016; Tjon-Kon-Fat et al., 2016). Newer respiratory pathogens are also emerging. In view of this, we investigated the association of human PARV4 virus with SARI.

Parvovirus 4 (PARV4) is a newly discovered human Parvovirus, first reported in 2005 in serum of intravenous drug users infected with hepatitis B virus (Jones et al., 2005). PARV4 is a single stranded non-enveloped DNA virus belonging to the Parvoviridae family of genus Tetraparvovirus (Matthews et al., 2017). PARV4 infects a diverse range of hosts and has been classified into 3 genotypes; 1–3. Generally genotypes 1 and 2 are found in North America, Europe, and Asia, and genotype 3 is found in sub-Saharan Africa.

PARV4 has been detected in blood/plasma, autopsy samples, stool, nasopharyngeal swab, the bone marrow and CSF; however, until now, there are no established clinical manifestations of PARV4 infection (Simmonds et al., 2007a). It remains uncertain whether PARV4 actually causes the observed disease, or is a bystander that was coincidentally detected in a highly exposed population. Seroprevalence of PARV4 in the general population has been varying in different parts of the world ranging from 0% to 25% (Sharp et al., 2012; Lavoie et al., 2012). A study from Africa reports PARV4 in 0.8% of nasal swab specimens, whereas a study from Scotland did not observe PARV4 in respiratory samples (Drexler et al., 2012; Manning et al., 2006).

To the best of our knowledge, no previous study has reported the association of PARV4 with severe acute respiratory illness (SARI). It is also not clear whether PARV4 is transmitted by the

* Corresponding author.

E-mail addresses: shantanukgm@gmail.com (S. Prakash),
shukla_suruchi@yahoo.com (S. Shukla), vangala005@gmail.com (V. Ramakrishna),
hricha2008@gmail.com (H. Mishra), mnbhagat3@gmail.com (A.K. Bhagat),
virology.net@gmail.com (A. Jain).

1 Both contributed equally towards the manuscript.

https://doi.org/10.1016/j.ijid.2019.10.001
1201-9712/© 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
respiratory route or causes respiratory infections. Here, we aim to investigate the association of human PARV4 with SARI.

Methods

Case definition (SARI)

A person of any age who presented with difficulty in breathing accompanied with fever ≥38 °C and cough with at least one of the following symptoms: poor general condition, thoracic pain, polynoena or acute respiratory distress syndrome (ARDS) and required hospitalization (World Health Organization) (WHO, 2013). This study was ethically approved by the Institutional ethics committee (ethical clearance reference code: Registration No. ECR/262/Inst/UP/2013/RR/16). All cases and controls or their guardians provided written informed consent for participation in the study. Consenting subjects were consecutively enrolled. Demographic and clinical details were collected through a predesigned questionnaire.

Laboratory diagnosis

For conducting this case control study, NS/TS from cases referred to Virology Laboratory, Department of Microbiology, King George’s Medical University, Lucknow, Uttar Pradesh, India, with clinical diagnosis of SARI and healthy volunteer controls (matched for age and sex), over a period of 15 months, i.e. January 2017 to March 2018, were collected and tested for viral etiology (Influenza A/Subtype H1N1/Subtype H3N2/ Influenza B, Para-influenza virus (PIV), Measles virus (MEV), Respiratory syncytial virus RSV, Adenovirus (AV), Bocavirus (BoV), as per previously reported method (Singh et al., 2014) and human house-keeping control RnaseP (Shu et al., 2011). Each real time PCR consisted of positive, negative and extraction controls. The result was reported only if all the controls were valid. All the samples of both cases (SARI) and controls were also tested for presence of PARV4-DNA using primers and probes described in patent no. PCT/IN2015/000409 and WO2016071926A9 by Jain and Prakash (2016). Total viral nucleic acid was extracted from 200 μl NS/TS sample using PureLink DNA/RNA mini kit (Invitrogen, USA) as per manufacturer’s instructions and processed for TaqMan real time PCR. The real time PCR reaction mix contained 12.5 μl 2X master mix (LightCycler 480 Probes Master, Roche Diagnostics, Netherlands BV, Almere, the Netherlands), 1 μl of PARV4 forward and reverse primer (10 pm/μl) and 0.5 μl taqmanprobe (10 pm/μl)(IDT, USA) and 5 μl H2O (DNase and RNase free). Finally, 5 μl extracted total nucleic acid was added to 20 μl of prepared mastermix, making it a final volume of 25 μl. Real time RT-PCR assays were performed on Quantstudio 7 (Life Technologies, USA).

DNA sequencing and analysis

PARV4 VP1 gene was amplified using an in-house designed nested PCR primer to yield a product size of 849–854 base pairs (bp). The amplified nested PCR product was purified using exonuclease I and Shrimp Alkaline phosphatase. The amplicon was processed for sequencing PCR using BigDye Terminator (BDT) cycle sequencing kitv3.1 (Applied Biosystems, Foster City, CA). After sequencing PCR the product was purified using an ethanol purification method and sequenced on Genetic Analyzer 3130 (Applied Biosystems) according to the manufacturer’s instructions. Sequences were aligned and the phylogenetic tree was constructed using MEGA 7 software (Kumar et al., 2016; Tamura et al., 2004). Reference sequences were obtained from GenBank [genotype 1: EU546204.1, genotype 2: EU175855.1, genotype 3: JN183925.1]. Data were analyzed using GraphPad Prism software version 5. Intergroup comparisons were done using Chi square test. P value< 0.05 was regarded as statistically significant.

Results

A total of 241 cases of SARI and 146 normal healthy controls were included in the study. Groups were compared for gender and age distribution. The mean age ± SD of cases was 23.26 ± 23.34 (Median 14; range 0–63) and of the control group was 18.0 ± 15.51 (median 4.5; range 0-62). Peak positivity of PARV4 was noted among infants and young children (age, 0–10years) as 46.87% (n=30/64) cases were younger than 5 years of age (Table 3). The seasonal distribution of PARV4 corresponds to the enrolled SARI cases. There was an upsurge in PARV4 positive cases in the month of January (Figure 1).

Of total 241 SARI cases, 64 (26.55%) were positive for at least one of the known tested respiratory pathogens. RSV [n = 19 (7.88%)] was the most common aetiology detected in cases, followed by Influenza A/H1N1 [n = 12 (4.97%) and MEV [n = 12 (4.97%)] (Table 1). Four cases were positive for more than one virus [Influenza A/H1N1 + MEV (2), Influenza B + Adenovirus (1); PIV + MEV (1)]. PARV4-DNA was present in 64 cases. A total of 44(18.2%) cases had PARV4 DNA alone, whereas in 20 cases (8.2%) PARV4 was co-detected with other known pathogenic viruses (Table 2). Parovirus 4 was significantly higher in cases as compared to controls (Relative risk 37.70955%; NNT (Harm) 3.868: 95% CI: 5.402 (Harm) to 3.013 (Harm); p value<0.0003).

Of 146 healthy controls, three subjects were positive for RSV, one for PIV, whereas in a single individual PARV4-DNA was found (Tables 1 and 2).

Out of total viral causes tested, a final aetiology could be established in 108(44.81%) cases which were positive for at least one of the tested viral agents. Of 64 PARV4 positive cases, 23

Table 1

| Virus                              | Positivity in SARI cases N = 241(%) | Positivity in controls N = 146(%) |
|------------------------------------|------------------------------------|----------------------------------|
| Influenza A/H1N1                   | 12(4.97)                           | 0.00                             |
| Influenza B                        | 11(4.56)                           | 0.00                             |
| Para influenza virus (PIV)         | 6(2.48)                            | 1(0.68)                          |
| Adenovirus                         | 5(2.07)                            | 0.00                             |
| Bocavirus                          | 3(1.24)                            | 0.00                             |
| Respiratory syncytial virus (RSV)  | 19(7.88)                           | 3(1.20)                          |
| Measles virus (MEV)                | 12(4.97)                           | 0.00                             |
| Human metapneumovirus (HMPV)       | 0.00                               | 0.00                             |
| Total etiology positive            | 68(28.21)                          | 4(2.73)                          |
| Total cases positives              | 64(26.55)                          | 4(2.73)                          |

Abbreviation: Influenza A (InfA), Influenza B (Inf B), Parainfluenza virus (PIV), Measles virus (MEV), Respiratory syncytial virus (RSV), Adenovirus (AV), Bocavirus (BoV), Human Metapneumovirus (HMPV), Parvo 4 Virus (PARV4).

* 4 patients were positive for more than one pathogens (2 with Influenza A (H1N1) and Measles, 1 Influenza B with Adenovirus and 1 Measles with Para-influenza virus).
Table 2
PARV4 virus positivity among cases and control group.

|                       | Only PARV4 virus positive | Infl A/H1N1 + PARV4 | Infl B + PARV4 | PIV + PARV4 | AV + PARV4 | RSV + PARV4 | MEV + PARV4 | Infl A/H1N1 + MEV + PARV4 | Infl B + AV + PARV4 | Total PARV4 positive |
|-----------------------|---------------------------|---------------------|----------------|-------------|------------|------------|------------|----------------------------|---------------------|----------------------|
| SARI cases N=241(%)   | 44(18.2)                  | 2(0.83)            | 6(2.49)       | 1(0.41)     | 1(0.41)    | 5(2.07)    | 3(1.24)    | 1(0.41)                                  | 1(0.41)            | 64(26.55)           |
| Healthy controls N=146(%) | 1(0.68)                  | 0(0)               | 0(0)          | 0(0)        | 0(0)       | 0(0)       | 0(0)       | 0(0)                                      | 0(0)               | 1(0.68)             |
| Statistical association (p-value) | <0.05                      | NA                 | NA            | NA          | NA         | NA         | NA         | NA                                          | NA                  | <0.05               |

Abbreviation: Influenza A (InflA), Influenza B (Infl B), Parainfluenza virus (PIV), Measles virus (MEV), Respiratory syncytial virus (RSV), Adenovirus (AV), Bocavirus (BoV), Human Metapneumovirus (HMPV), Parvo 4 Virus (PARV4).
NA = Not Applicable.

Table 3
Age and gender distribution of PARV4 positive cases.

| Age/gender distribution | Cases N=241(%) | Total PARV4 positive cases 64(%) | Cases positive for PARV4 only 44(%) | Co-infected 20cases [PARV4 + any other aetiology] positive (%) |
|-------------------------|----------------|---------------------------------|-------------------------------------|---------------------------------------------------------------|
|                         | Male           | Female                         | Male                                | Female                                      | Male           | Female                         |
| 0–5 yrs                 | 67(27.80)      | 17(7.05)                       | 22(9.04)                            | 12(27.27)                          | 10(50.00)      | 4(20.00)                       |
| >5–10 yrs               | 18(7.47)       | 3(1.24)                        | 4(6.25)                             | 2(4.54)                           | 0(0)           | 0(0)                           |
| >10–15 yrs              | 14(5.81)       | 7(2.93)                        | 7(10.94)                            | 3(6.81)                           | 1(2.27)      | 2(10.00)                       |
| >15–25 yrs              | 14(5.81)       | 7(2.93)                        | 3(6.81)                             | 3(6.81)                           | 0(0)           | 0(0)                           |
| >25–40 yrs              | 11(4.56)       | 21(8.71)                       | 2(3.13)                             | 2(3.13)                           | 0(0)           | 1(5.00)                       |
| >40–70 yrs              | 29(12.03)      | 21(8.71)                       | 4(6.25)                             | 4(6.25)                           | 0(0)           | 0(0)                           |
| >70 yrs                 | 6(2.49)        | 2(0.83)                        | 1(1.26)                             | 1(1.26)                           | 0(0)           | 0(0)                           |
| Total                   | 159(65.97)     | 82(34.02)                      | 43(67.18)                           | 21(32.81)                          | 30(68.18)     | 14(31.81)                      |
|                         |                |                                 |                                     |                                 | 13(65.00)     | 7(35.00)                       |

Figure 1. Month-wise distribution (%) of total cases tested and positive cases.

Table 2: Overall distribution of SARI (%) n=241
Table 3: SARI cases positive for any etiology tested (%) n=108
Table 3: PARV4 cases positive for viral etiology other than PARV4 (%) n=64
Table 3: SARI cases positive for PARV4 only (%) n=44

Discussion
The present study described a high prevalence of PARV4 DNA in cases presenting with SARI. An association of PARV4 positivity with SARI is also seen. Clinical impact of PARV4 infection is not well understood; still, a wide range of potential infection outcomes has been proposed. In the past, studies have described an association of PARV4 with influenza-like symptoms, encephalitis (Benjamin et al., 2011; Prakash et al., 2015), transient rash and hepatitis (Sharp et al., 2012), foetal hydrops (Chen et al., 2011) and acceleration of progression to AIDS in HIV-infected adults (Simmons et al., 2012). Transmission via respiratory secretions or faeces suggestive of respiratory tract infection or gastroenteritis is also suggested. Groups with risk factors for parenteral infection and those infected with either HBV or HCV or HIV have associated PARV4 infections, suggesting parenteral transmission. Intravenous drug users and those with a history of multiple transfusions have a

samples with high viremia (Ct value <30) could be amplified for the VP1 gene and sequenced. Phylogenetic analysis showed the presence of PARV4 genotype 2 in SARI cases (Figure 2). One strain from a healthy control was sequenced and was similar to other strains detected in cases. All the genetic sequences were submitted to GenBank (accession numbers MH939288 to MH939311).

Discussion
The present study described a high prevalence of PARV4 DNA in cases presenting with SARI. An association of PARV4 positivity with SARI is also seen. Clinical impact of PARV4 infection is not well understood; still, a wide range of potential infection outcomes has been proposed. In the past, studies have described an association of PARV4 with influenza-like symptoms, encephalitis (Benjamin et al., 2011; Prakash et al., 2015), transient rash and hepatitis (Sharp et al., 2012), foetal hydrops (Chen et al., 2011) and acceleration of progression to AIDS in HIV-infected adults (Simmons et al., 2012). Transmission via respiratory secretions or faeces suggestive of respiratory tract infection or gastroenteritis is also suggested. Groups with risk factors for parenteral infection and those infected with either HBV or HCV or HIV have associated PARV4 infections, suggesting parenteral transmission. Intravenous drug users and those with a history of multiple transfusions have a
high positivity of PARV4 (Jones et al., 2005; Simmonds et al., 2007b; Fryer et al., 2007a).

In the present study, we have tested respiratory samples from many healthy individuals and except for one, all were negative. Studies from Africa have reported the detection frequency of PARV4 IgG ranging from 30% to 50% in the general population, irrespective of their positivity for HBV/ HCV/ HIV (Lavoie et al., 2012; Drexler et al., 2012; Sharp et al., 2010). Acute infections with PARV4 DNA positivity were seen in 8.5% of young children in Ghana (Drexler et al., 2012).

Genotype 2 was the only circulating genotype detected in the present study. Genotype-2 (formerly known as PARV5) has been identified in European and North American cohorts (Matthews et al., 2017; Simmonds et al., 2008; Fryer et al., 2007b). It was also the predominant strain reported from Asia (Matthews et al., 2017; Benjamin et al., 2011). In one of our earlier studies we also found genotype 2 in samples from cases of encephalitis (Prakash et al., 2015). There is a high similarity in strains of genotype 2 identified the world over.

Higher positivity in children less than 5 years of age and during winter is demonstrable with the current data. Most of the studies have commented on positivity in children; however, seasonality is not well described (Panning et al., 2010; Rosenfeldt et al., 2015; von Linstow et al., 2015). Co-infection with other respiratory viruses is also seen in the present study. It may be possible that PARV4 exacerbated other viral infections. However there is no supporting literature suggesting the same. Our study has a limitation that it does not include the co-existence or presence of non viral
etiolologies. Our study also did not look at the prevalence in cases with milder illness for providing a comparison with prevalence in cases with SARI.

**Conclusion**

Detection of PARV4 in a significantly large number of SARI cases, in comparison with controls, suggests association of PARV4 with SARI. PARV4 genotype 2 is the only circulating strain detected in our study.

**Conflict of interest**

The authors have declared no conflict of interest.

**Funding**

The financial support was provided by the Department of Health Research, New Delhi.

Ethical reference number: ECR/262/Inst/UP/2013/RR/16.

**Author’s contributions**

All authors reviewed and approved the final version. SP, SS & AJ consequently contributed to drafting and editing. HM, AKB & RV contributed to methodology and results of scientific work.

**Acknowledgement**

We acknowledge staff of the virology laboratory, Department of Microbiology, King George’s Medical University, Lucknow, for their support.

**References**

Benjamin LA, Lethwaite P, Vasanthapuram R, et al. Human parvovirus 4 as potential cause of encephalitis in children, India. Emerg Infect Dis 2011;17(8):1484–7.

CDC. Overview of influenza surveillance in United States. Available from: USA: Department of Health and Human Services, Center for Disease Control; 2016. https://www.cdc.gov/flu/weekly/overview.htm.

Chakravorty G, Wagner AL, Power LE, Janusz CB, Machabishvili A, Karseladze I, et al. Severe Acute Respiratory Infection (SARI) sentinel surveillance in the country of Georgia, 2015–2017. PLoS One 2018;13(7):e0201497.

Chen MY, Yang SJ, Hung CC. Placental transmission of human parvovirus 4 in newborns with hydrops, Taiwan. Emerg Infect Dis 2011;17(10):1954–6.

Drexler JF, Reber U, Muth D, et al. Human parvovirus 4 in nasal and fecal specimens from children, Ghana. Emerg Infect Dis 2012;18(10):1650–3.

Fryer JF, Lucas SB, Padley D, et al. Parvoviruses PARV4/5 in hepatitis C virus-infected patient. Emerg Infect Dis 2007a;13(1):175–6.

Fryer JF, Delwart E, Hecht FM, et al. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion 2007b;47(6):1054–61.

GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017;17(11):1133–61.

Jain A, Prakash S. In-vitro detection of human parvovirus 4. 2016 PCT/IN2015/000469 and WO2016071926A5.

Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E. New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005;79:8230–6.

Kennison S, Tchendjou P, Vernet MA, Moyo-Tetang S, Mossius T, Nnjakoou-Ripa M, et al. Viral etiology of severe acute respiratory infections in hospitalized children in Cameroon, 2011–2013. Influenza Respir Viruses 2016;10(September 5):386–93 Epub 9 May 2016.

Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol 2016;33(7):1870–4.

Laguna-Torres VA, Sanchez-Laraespada JF, Lorenzana I, Forshay B, et al. Influenza and other respiratory viruses in three Central American countries. Influenza Respir Viruses 2011;5:123–34.

Lavoie M, Sharp CP, Pépin J, Pennington C, Foupouapouognigni Y, Bybus OG, et al. Human parvovirus 4 infection, Cameroon. Emerg Infect Dis 2012;18(4):680–3.

Manning A, Russell V, Eastick K, Leadbetter GH, Hallam N, Templeton K, et al. Epidemiological profile and clinical associations of human Bocavirus and other human parvovirus. J Infect Dis 2006;194:1283–90.

Matthews PC, Sharp C, Simmonds P, Klennerman P. Human parvovirus 4 “PARV4” remains elusive despite a decade of study. F1000Research 2017;6:82 Published 27 January 2017.

Panning M, Kobbe R, Vollbach S, et al. Novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg Infect Dis 2010;16(7):1143–6.

Prakash S, Jain A, Seth A, Lindberg E, et al. Complete genome sequences of two isolates of human parvovirus 4 from patients with acute encephalitis syndrome. Genome Announc 2015;3(1): pii: e01472–14.

Rosenfeldt V, Norja P, Lindberg E, et al. Low prevalence of Parvovirus 4 in HIV-infected children in Denmark. Pediatr Infect Dis J 2015;34(7):761–2.

Sharp CP, Vermeulen M, Něháš Y, et al. Changing epidemiology of human parvovirus 4 infection in sub-Saharan Africa. Emerg Infect Dis 2010;16(10):1605–7.

Sharp CP, Lai A, Donfield S, Comperts ED, Simmonds P. Virolologic and clinical features of primary human parvovirus 4 infection in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion 2012;52:1482–9.

Shu B, Wuu KH, Emery S, Villanueva J, Johnson R, Guthrie E, et al. Design and performance of the CDC real-time RT-PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus. J Clin Microbiol 2011;49(7):2614–9.

Simmonds P, Manning A, Kenne11 R, Cane11 FW, Bell JF. Parenteral transmission of the novel human parvovirus PARV4. Emerg Infect Dis 2007a;13:1386–8.

Simmonds P, Manning A, Kene11 R, et al. Parenteral transmission of the novel human parvovirus PARV4. Emerg Infect Dis 2007b;13(9):1386–8.

Simmonds P, Douglas J, Bestetti G, et al. A third genotype of the human parvovirus PARV4 in sub-Saharan Africa. J Gen Virol 2008;89(pt 9):2299–302.

Simmons R, Sharp C, McClure CP, et al. Parvovirus 4 infection and clinical outcome in high-risk populations. J Infect Dis 2012;205(12):1816–20.

Singh AK, Jain A, Jain B, Singh KP, Dangi T, Mohan M, et al. Viral aetiology of acute lower respiratory tract illness in hospitalised paediatric patients of a tertiary hospital: one year prospective study. Indian J Med Microbiol 2014;32:13–8.

Tamura K, Nis M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci U S A 2004;101:11030–5.

Tjon-Kon-Fat R, Me Hof F, Nikisins S, Pires J, Pereyaslav D, Gross D, et al. The potential risks and impact of the start of the 2015-2016 influenza seasons in the WHO European Region: a rapid risk assessment. Influenza Respir Viruses 2016;10:236–46.

von Linstow ML, Rosenfeldt V, Lindberg E, et al. Absence of novel human parvovirus (Parvovirus 4) in Danish mothers and children. J Clin Virol 2015;65:23–5.

WHO. Global epidemiological surveillance standards for influenza. 2013. http://www.who.int/influenza/resources/documents/WHO_Epidemiological_Influenza_Surveillance_Standards_2014.pdf.

WHO. Global epidemiological surveillance standards for influenza. 2013. http://www.who.int/influenza/resources/documents/WHO_Epidemiological_Influenza_Surveillance_Standards_2014.pdf.

World Health Organization. Acute respiratory infections in children. 2011. http://www.who.int/pmnch/media/press_materials/fs/fs_mdg4_childmortality/en/.